Stockscreener 앱 받기
1.43
7.74%
-0.12
시간 외 거래:
1.43
전일 마감가:
$1.55
열려 있는:
$1.55
하루 거래량:
142.89K
Relative Volume:
0.59
시가총액:
$106.31M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.4569
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-5.92%
1개월 성능:
-28.86%
6개월 성능:
-39.15%
1년 성능:
+10.85%
1일 변동 폭
$1.415
$1.56
1주일 범위
$1.415
$1.83
52주 변동 폭
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
678-392-3419
주소
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.43 | 128.61M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Entry Confirmation Using Short-Term Forecasting - Newser
Chart based analysis of Inhibikase Therapeutics Inc. trendsDaily Entry Opportunity Forecasting Tool - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Reversal Pattern Insights with Entry Tips - Newser
How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser
Automated trading signals detected on Inhibikase Therapeutics Inc.AI-Powered Stock Trend Movement Analysis - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser
Using fundamentals and technicals on Inhibikase Therapeutics Inc.Top Stock Picks with Forecast Accuracy - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser
How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataFree Real Time Stock Movement Analysis - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockChart Driven Opportunity Scanner with Alerts - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceFree Early Entry Tips With Low Risk Zone - Newser
Published on: 2025-08-06 00:58:01 - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockPortfolio Allocation Strategy for Stability - Newser
Published on: 2025-08-04 16:30:58 - metal.it
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free AI Driven Buy Alert Trade Blueprint - Newser
What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News
How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News
Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
What drives Inhibikase Therapeutics Inc. stock priceMaximize gains with data-driven trading alerts - Jammu Links News
What are Inhibikase Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison - Defense World
Published on: 2025-08-01 22:50:53 - Newser
Intraday pattern recognizer results for Inhibikase Therapeutics Inc.ROI Focused Watchlist with Trade Confidence - Newser
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):